Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.0364 | 0.4562 | 1 |
Leishmania major | proteasome beta 5 subunit, putative | 0.0364 | 0.4562 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0632 | 0.9887 | 1 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0364 | 0.4562 | 1 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.0364 | 0.4562 | 0.5 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.0364 | 0.4562 | 1 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.0364 | 0.4562 | 1 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.0364 | 0.4562 | 1 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.0364 | 0.4562 | 1 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.0364 | 0.4562 | 1 |
Schistosoma mansoni | proteasome catalytic subunit 2 (T01 family) | 0.0638 | 1 | 1 |
Echinococcus granulosus | proteasome subunit beta type 7 | 0.0638 | 1 | 1 |
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.0364 | 0.4562 | 1 |
Echinococcus multilocularis | proteasome subunit beta type 7 | 0.0638 | 1 | 1 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.0364 | 0.4562 | 1 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.0364 | 0.4562 | 1 |
Mycobacterium ulcerans | short chain dehydrogenase | 0.0632 | 0.9887 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
FC (binding) | = 0.93 | Activation of Nrf2 in human NPC-TW01 or HONE1 cells expressing ARE-luciferase at 20 uM incubated for 16 hrs by luciferase reporter gene assay relative to untreated control | ChEMBL. | 25907366 |
IC50 (ADMET) | > 50 uM | Cytotoxicity against human Jurkat cells assessed as reduction in cell viability by MTT assay | ChEMBL. | 25907366 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.